Загрузка...
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells
BACKGROUND: Docetaxel is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to docetaxel therapy and their disease will continue to progress. The mechanisms by which resistance develops are still inc...
Сохранить в:
| Опубликовано в: : | Prostate |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5448975/ https://ncbi.nlm.nih.gov/pubmed/28485104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23358 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|